SecBot SecBot
PRESS-RELEASE ·Filed Nov 13, 2026

WVE

Wave Life Sciences USA, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed3d 18h ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

The Phase 1 data support continued development but are early and from a relatively low-BMI cohort. The key catalyst is the Phase 2a six-month data in 2027, which will include body composition and liver fat measurements. Monitor for enrollment updates and any safety signals from the combination trial with tirzepatide.

DirectionNeutral
Confidencemedium
Horizonmonths

Drug in focus

WVE drug pipeline →

WVE-007

● Neutral Named in this press release
Impact
Phase
Phase 1/2a
Time to market
Several years away — still in Phase 1/2a with no regulatory filing submitted. If Phase 2a data are positive, a Phase 3 program would likely take 2-3+ years, followed by an FDA submission. Best-case timeline to potential approval is likely 2029-2030 at the earliest.
Next catalyst
None dated

What to watchThe next catalyst is the initiation of the post-incretin maintenance trial, expected in Q4 2026 (imminent). Beyond that, Phase 2a combination-trial data (WVE-007 + tirzepatide) and 12-month monotherapy data are the next meaningful readouts, though no specific dates are set. A positive maintenance-trial initiation or combination data could re-rate the stock from its depressed levels, but the high short interest (~10.7% of outstanding) and intense GLP-1 competition mean any miss would likely be punished severely.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$3.13
T+0 close · Nov 13, 2026 · via day close
Latest settled
−8.31%
T+1 · $2.87
Vs SPY
−6.40%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $3.13entry
  2. T+1 · 20h ago −8.31%α −6.40% · $2.87
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Wave Life Sciences presented Phase 1 data for WVE-007, an siRNA targeting INHBE for obesity, at ObesityWeek 2026. The data showed durable Activin E reductions (82-88% mean maximum) and body composition improvements with preserved lean mass after a single dose, with no drug-related serious adverse events. The company also announced integration of its maintenance trial with an ongoing Phase 2a combination trial with tirzepatide, with six-month Phase 2a data expected in 2027.

Key Facts

  • Phase 1 data showed single-dose Activin E reductions of 82%, 84%, and 88% mean maximum in top three dose cohorts (240 mg, 400 mg, 600 mg).
  • In the 240 mg cohort, placebo-adjusted reductions in visceral fat, total fat, and waist circumference with lean mass preservation were observed one year after a single dose.
  • No drug-related serious adverse events, no discontinuations, and no clinically meaningful changes in lipids or liver function tests.
  • Phase 2a monotherapy trial in higher BMI (35-50 kg/m²) individuals is ongoing; six-month data expected in 2027.
  • Wave plans to integrate its maintenance clinical trial with the ongoing Phase 2a combination trial of WVE-007 plus tirzepatide.
  • Baseline BMI in Phase 1 was 31.7 kg/m², lower than typical obesity trials; higher baseline BMI/adiposity was associated with greater treatment effect.

Financial Impact

No financial data provided; Phase 1 data is early-stage and non-revenue generating.

Risk Factors

  • Phase 2a data are not yet available; efficacy in higher-BMI population is unproven.
  • Competition from incretin-based therapies (e.g., tirzepatide, semaglutide) is well-established and commercially dominant.
  • The company is clinical-stage with no approved products or revenue; reliance on future financing is likely.
  • Integration of maintenance trial into combination trial may delay or complicate data readouts.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402569

Track record

16 reports on WVE

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +17.42% at T+5 after the Mar 26, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Viewing Entry $3.13 to $2.87 Now $2.87 −8.31% ▼ −8.31% −6.40% vs SPY
  2. Oct 27, 202620d ago SC 13G Neutral 4/10 Entry $3.64 to $3.63 Now $2.87 −21.15% ▼ −0.27% +0.11% vs SPY
  3. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $3.45 to $3.64 Now $2.87 −16.81% ▲ +5.51% +5.16% vs SPY
  4. Oct 27, 202620d ago 8-K Bullish 6/10 No price data
  5. Oct 27, 202620d ago Press Release Neutral 5/10 Entry $3.45 to $3.64 Now $2.87 −16.81% ▲ +5.51% +5.16% vs SPY
  6. Oct 14, 20264w ago DEF 14A Neutral 4/10 Entry $3.19 to $3.13 Now $2.87 −10.03% ▼ −1.88% −0.77% vs SPY
  7. Sep 30, 20266w ago Press Release Bullish 5/10 Entry $3.70 to $3.88 Now $2.87 −22.43% ▲ +4.86% +4.69% vs SPY
  8. Aug 13, 202613w ago Insider Cluster Neutral 3/10 Entry $5.41 to $5.09 Now $2.87 −46.95% ▼ −5.92% −5.44% vs SPY
  9. May 18, 202626w ago Press Release Bullish 7/10 Entry $6.14 to $6.19 Now $2.87 −53.26% ▲ +0.81% −0.23% vs SPY
  10. Apr 28, 202628w ago 8-K Bullish 7/10 No price data
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026